查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2018962

经导管心臟瓣膜市场：2026 年至 2032 年全球市场预测，按产品类型、瓣膜类型、输送途径、患者年龄层和最终用户划分。

Transcatheter Heart Valve Market by Product Type, Valve Type, Delivery Route, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，经导管心臟瓣膜市场价值将达到 44.3 亿美元，到 2026 年将成长至 49.6 亿美元，到 2032 年将达到 96.4 亿美元，年复合成长率为 11.74%。

主要市场统计数据
基准年 2025 44.3亿美元
预计年份：2026年 49.6亿美元
预测年份 2032 96.4亿美元
复合年增长率 (%) 11.74%

为高阶决策者提供有关现代经导管心臟瓣膜技术的重要指导，阐明关键的临床、营运和商业性问题。

经导管心臟瓣膜技术正从小众创新发展成为主流临床策略，彻底改变了结构性心臟疾病的诊断、治疗和管理方式。器械设计、影像引导和手术流程的改进降低了创伤性，并扩大了适合接受导管介入治疗的患者群体。因此，医院、专科诊所、器材製造商和保险公司正在重新思考治疗路径、资金分配和长期照护模式，以优先考虑创伤性较小的结构性心臟疾病介入治疗。

对推动经导管心臟瓣膜治疗新范式的临床、技术和操作方面的同步变化进行全面分析。

经导管心臟瓣膜治疗的格局正受到多项平行变革的重塑，这些变革正在重新定义临床路径和商业模式。首先，器械的迭代创新，包括密封裙边、重新定位机制和低轮廓输送系统的改进，拓展了手术选择范围并降低了併发症发生率。其次，多重模式影像和手术规划工具的成熟使得病患选择和器械尺寸选择更加精准，从而提高了手术的可预测性和治疗效果。

对 2025 年美国收费政策变化将如何重塑瓣膜治疗领域的供应策略、价格谈判和临床准入途径进行详细分析。

2025年实施的关税调整对整个经导管心臟瓣膜生态系统造成了一系列累积压力，影响了原料采购、零件进口以及全球製造地的经济效益。这些政策变化促使製造商重新审视与供应商的合同，并尽可能加快本地化策略的实施。近期由此产生的一个营运影响是，旨在减少对关税敏感零件依赖的供应链重组倡议有所增加，这反过来又影响了前置作业时间和库存管理实践。

策略性細項分析揭示了瓣膜类型、设备类别、输送途径、医疗保健环境和患者年龄层如何影响临床选择和商业化优先事项。

以瓣膜类型进行的分析突显了每种适应症的明确临床路径和器械要求：主动脉瓣、二尖瓣、肺动脉瓣和三尖瓣。由于主动脉瓣手术量大且解剖结构复杂，因此该区域持续推动平台技术的迭代创新；而二尖瓣和三尖瓣区域由于瓣膜解剖结构复杂且反流病理学异常，需要采用特殊的固定和密封技术。肺动脉瓣区域的应用仍主要集中在先天性疾病和术后患者群体，在这些领域，器械的小型化和柔软性至关重要。

对全球市场监管、报销和临床引入实践的差异如何影响瓣膜技术的策略市场进入和业务扩张决策进行区域评估。

美洲、欧洲、中东和非洲以及亚太地区的市场趋势差异显着，每个地区都展现出其独特的法规结构、报销模式和临床应用路径。在美洲，清晰的监管政策和完善的临床试验基础设施历来促进了新型瓣膜技术的早期应用；然而，与支付方的谈判动态以及保险体系的多样性会影响报销策略和医院的采购流程。同时，欧洲部分地区为实现监管协调所做的努力推动了跨国临床计画的发展，但各国不同的医疗技术评估流程导致产品上市时间和定价结构存在差异。

对决定经导管瓣膜生态系统竞争优势的企业策略、合作伙伴关係和创新重点进行了深入概述。

竞争格局呈现出多元化的特点，既有成熟的医疗设备製造商，也有专业零件供应商，还有不断突破设计与交付界线的敏捷型Start-Ups。主要企业采取了差异化策略，包括专注于投资下一代密封技术、拓展其输送系统产品组合，以及建构可满足多种阀门尺寸和适应症需求的模组化平台。医疗设备製造商与影像、数位医疗和服务供应商之间的策略合作，正在强化整合式医疗模式，从而改善手术规划和长期监测。

为行业领导者提供可操作且优先的策略建议，以增强临床准入、供应弹性、商业性差异化和长期价值交付。

领导企业应优先考虑整合随机数据与真实世界註册研究结果，从而建立综合证据，以支持临床导入和与支付方的沟通。透过将临床试验终点与真实世界疗效指标相匹配，企业可以为监管机构和支付方建立引人入胜的论证，简化导入流程。同时，投资灵活的生产策略和供应商多元化，既能维持产能以扩大规模，又能减轻贸易政策和零件采购中断的影响。

本报告详细介绍了一种高度透明的调查方法，该方法旨在确保对医疗设备的性能和市场动态有可靠的洞察，包括证据整合、专家参与和检验过程。

本研究途径结合了对同行评审的临床文献的系统性回顾、临床试验註册库的分析以及对监管指导文件的重点审查，以确定临床背景和安全性考虑。除此证据基础外，还对介入性心臟病专家、心臟外科医生、采购经理和监管专家进行了定性专家访谈，以了解他们对医疗设备推广应用障碍、培训需求以及性能差异等方面的实际观点。

将关键策略见解进行简洁整合，以指导经营团队决策，并使投资与永续的临床和商业性成果保持一致。

经导管心臟瓣膜领域正日趋成熟，成为一个复杂的生态系统，器械创新、不断发展的临床实践和商业策略在此交汇融合。器材设计和影像技术的进步正在扩大患者群体并优化治疗效果，同时，监管和报销体係也在不断调整，以支持迭代改进和更广泛的医疗服务。同时，贸易政策和供应链限制等外部压力正在加速製造商和医疗系统采取战略应对措施。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 经导管心臟瓣市场：依产品类型划分

  • 球囊扩张型
  • 机械膨胀型
  • 自膨胀

第九章 经导管心臟瓣膜市场：瓣膜类型

  • 主动脉瓣
  • 二尖瓣
  • 肺动脉
  • 三尖瓣

第十章 经导管心臟瓣膜市场（依输送途径划分）

  • 经主动脉
  • 顶端通路
  • 股动脉通路
  • 锁骨下通路

第十一章 依病患年龄组别分類的经导管心臟瓣膜市场

  • 成年患者
  • 儿童患者

第十二章 经导管心臟瓣膜市场：依最终用户划分

  • 门诊手术中心及诊所
  • 医院和心臟中心

第十三章 经导管心臟瓣膜市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 经导管心臟瓣膜市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 经导管心臟瓣膜市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国经导管心臟瓣膜市场

第十七章：中国经导管心臟瓣膜市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 4C Medical Technologies, Inc.
  • Abbott Laboratories
  • Auto Tissue Berlin GmbH
  • Boston Scientific Corporation
  • Bracco SpA
  • Colibri Heart Valve, LLC
  • CoreMedic
  • Cryolife Inc.
  • Edwards Lifesciences Corporation
  • Foldax, Inc.
  • Hansen Medical Inc. by Auris Surgical Robotics Inc.
  • JC Medical, Inc. by Genesis Group
  • JenaValve
  • Lepu Medical Technology Co., Ltd
  • LivaNova PLC
  • Mardil Medical
  • Medtronic PLC
  • Meril Life Sciences
  • NVT AG
  • SentreHEART by AtriCure
  • Stryker Corp.
  • XELTIS
Product Code: MRR-EC2E133E334A

The Transcatheter Heart Valve Market was valued at USD 4.43 billion in 2025 and is projected to grow to USD 4.96 billion in 2026, with a CAGR of 11.74%, reaching USD 9.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.43 billion
Estimated Year [2026] USD 4.96 billion
Forecast Year [2032] USD 9.64 billion
CAGR (%) 11.74%

An essential orientation to contemporary transcatheter heart valve innovation that frames clinical, operational, and commercial imperatives for senior decision-makers

Transcatheter heart valve technologies have moved from niche innovation to mainstream clinical strategy, catalyzing a shift in how structural heart disease is diagnosed, treated, and managed. Improvements in device design, imaging guidance, and procedural workflows have reduced invasiveness and expanded the population eligible for catheter-based interventions. As a result, hospitals, specialty clinics, device manufacturers, and payers are reassessing treatment pathways, capital allocation, and long-term care models to align with a trajectory that favors less invasive structural interventions.

This transition has been accompanied by increased collaboration between clinical leaders, engineering teams, and commercial strategists to accelerate safe adoption while controlling costs and protecting outcomes. In addition, regulatory authorities have updated pathways to reflect iterative device improvements and to harmonize evidence requirements across jurisdictions. Clinicians are now balancing established surgical conventions with expanding percutaneous options, requiring robust clinical governance and outcome monitoring that integrates real-world evidence with randomized trial data.

Consequently, executives must understand not only the technical attributes of new valve platforms but also the economic, logistical, and clinical ecosystem changes that drive adoption. This report synthesizes those dynamics into actionable insight so stakeholders can make informed choices about product development, service delivery, and strategic partnerships in a rapidly maturing field.

Comprehensive analysis of concurrent clinical, technological, and operational shifts that are driving a new paradigm for transcatheter heart valve care delivery

The landscape of transcatheter heart valve care is being reshaped by several concurrent transformative shifts that are redefining clinical pathways and commercial models. First, iterative device innovation-encompassing refinements in sealing skirts, repositionability mechanisms, and lower-profile delivery systems-has expanded procedural options and reduced complication profiles. Second, the maturation of multimodality imaging and procedural planning tools has enabled more precise patient selection and device sizing, thereby improving procedural predictability and outcomes.

Third, care delivery models are decentralizing as ambulatory surgical centers and specialized clinics assume an increasing role in low-complexity interventions, supported by standardized protocols and enhanced peri-procedural pathways. Fourth, there is a growing focus on lifecycle management of valve recipients, with registries and digital monitoring platforms capturing longitudinal outcomes that inform both clinical practice and regulatory decision-making. Fifth, supply chain partnerships and manufacturing flexibility have become strategic imperatives, enabling companies to respond rapidly to demand shifts and device iterations while managing component sourcing risk.

Collectively, these transformations are driving new commercial partnerships, payer dialogues, and cross-functional collaborations within health systems. Stakeholders that integrate clinical evidence, operational efficiency, and strategic manufacturing will be best positioned to capture value as the field continues to evolve.

In-depth exploration of how 2025 tariff policy changes in the United States are reshaping supply strategies, pricing negotiations, and clinical access pathways in the valve sector

Tariff adjustments introduced in 2025 have introduced a set of cumulative pressures across the transcatheter heart valve ecosystem, affecting raw material sourcing, component imports, and the economics of global manufacturing footprints. These policy changes have prompted manufacturers to reassess supplier contracts and to accelerate localization strategies where feasible. The immediate operational consequence has been an uptick in supply chain redesign initiatives aimed at mitigating exposure to tariff-sensitive components, which in turn has influenced lead times and inventory practices.

In response, procurement teams have emphasized dual-sourcing and component standardization to preserve production continuity while negotiating pricing volatility. Regulatory and quality teams have also been engaged earlier in supplier qualification processes to ensure compliance with both device safety standards and evolving trade regulations. Clinically, some institutions have experienced temporary disruptions in device availability that necessitated modified scheduling practices and contingency planning to maintain patient access to timely interventions.

From a commercial perspective, increased landed costs have intensified discussions with payers around appropriate reimbursement adjustments and bundle pricing. At the same time, some manufacturers have explored value-engineering initiatives and process efficiencies to offset higher import costs without undermining clinical performance. Ultimately, the tariffs have accelerated strategic choices about manufacturing localization, supplier diversification, and commercial contracting that will have lasting implications for cost structures and market competition.

Strategic segmentation analysis revealing how valve type, device class, delivery route, care setting, and patient age groups drive clinical choice and commercialization priorities

Analysis across valve type highlights distinct clinical pathways and device requirements for aortic, mitral, pulmonary, and tricuspid indications. The aortic space continues to drive iterative platform innovation due to high procedure volumes and diverse anatomical challenges, whereas the mitral and tricuspid domains demand specialized anchoring and sealing approaches because of complex valve anatomy and regurgitant pathophysiology. Pulmonary applications remain focused on congenital and post-surgical populations where device miniaturization and flexibility are paramount.

Product type segmentation between balloon-expandable, mechanically expandable, and self-expandable technologies underpins strategic differentiation. Balloon-expandable platforms offer precise radial force characteristics suitable for calcified anatomies, mechanically expandable designs emphasize repositionability and controlled deployment, and self-expandable options provide conformability in irregular annuli and are often selected for their recapture capabilities. These technical distinctions inform clinical training requirements, inventory strategies, and post-market surveillance priorities.

Delivery route considerations across transaortic, transapical, transfemoral, and transsubclavian approaches indicate that transfemoral access remains the least invasive pathway when anatomy permits, whereas transapical and transaortic routes are reserved for complex anatomies or when peripheral access is limited. Each delivery route carries specific imaging and antithrombotic management implications that affect peri-procedural workflows.

End user segmentation that compares ambulatory surgical centers and clinics with hospitals and cardiac centers reveals divergent infrastructure needs. Ambulatory settings require streamlined instrumentation, rapid turnover protocols, and clear escalation pathways, while hospitals and cardiac centers must sustain broader multidisciplinary teams, hybrid operating environments, and comprehensive post-procedural monitoring. Finally, patient age group segmentation that distinguishes adult patients from pediatric patients drives differences in device sizing, long-term durability expectations, and lifelong follow-up strategies, with pediatric care emphasizing growth accommodation and minimization of reintervention burden.

Regional assessment of how divergent regulatory, reimbursement, and clinical adoption realities across global markets shape strategic entry and scaling decisions for valve technologies

Market behavior varies considerably across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct regulatory frameworks, reimbursement paradigms, and clinical adoption curves. In the Americas, regulatory clarity and established clinical trial infrastructures have historically enabled earlier adoption of novel valve technologies, while payer negotiation dynamics and heterogeneous insurance landscapes influence reimbursement strategies and hospital procurement processes. Conversely, regulatory harmonization efforts across parts of Europe have supported multi-country clinical programs, yet country-level health technology assessment processes drive differentiated adoption timing and pricing structures.

The Middle East & Africa region typically demonstrates pockets of advanced tertiary cardiac care concentrated in major urban centers, with adoption patterns influenced by public-private partnerships and medical tourism flows. In contrast, Asia-Pacific exhibits rapid procedural growth in certain markets driven by demographic trends and increasing investment in structural heart programs, although regulatory timelines and domestic manufacturing initiatives differ significantly by country.

Across regions, clinical training, registry participation, and post-market surveillance practices vary, underscoring the necessity for tailored market-entry strategies. Manufacturers and health systems must therefore align regulatory submissions, commercial models, and clinician education programs to regional norms while leveraging global evidence to accelerate local adoption.

Insightful overview of corporate strategies, alliance frameworks, and innovation priorities that are determining competitive advantage in the transcatheter valve ecosystem

The competitive environment is characterized by a mix of established device manufacturers, specialized component suppliers, and agile start-ups that are pushing the boundaries of design and delivery. Leading players have pursued differentiated strategies such as focused investments in next-generation sealing technologies, expansion of delivery system portfolios, and the establishment of modular platforms to support multiple valve sizes and indications. Strategic partnerships between device firms and imaging, digital health, and services providers have reinforced integrated care models that improve procedural planning and longitudinal monitoring.

Mergers and acquisitions, selective licensing deals, and co-development alliances have been used to accelerate capability expansion, particularly in areas such as leaflet materials, polymer science, and advanced manufacturing techniques like additive manufacturing. Concurrently, smaller innovators are concentrating on niche indications or on incremental improvements that address specific procedural complications. This dual pathway of sustained large-scale platform evolution and targeted niche innovation fosters a diverse pipeline that continues to expand clinical options.

Commercially, companies are strengthening value proposition narratives that combine clinical outcomes, cost-effectiveness analyses, and service-level guarantees to secure long-term contracts with health systems. Investment in training academies and proctor networks has become a differentiator, enabling faster adoption by offering hands-on experience and standardized procedural training. Overall, firms that integrate product excellence with robust service models and strategic partnerships will sustain competitive advantage.

Actionable and prioritized strategic recommendations for industry leaders to strengthen clinical adoption, supply resilience, commercial differentiation, and long-term value delivery

Leaders should prioritize integrated evidence generation that blends randomized data with real-world registry outcomes to support clinical adoption and payer engagement. By aligning clinical trial endpoints with real-world performance metrics, organizations can generate persuasive narratives for both regulators and payers, thereby smoothing adoption pathways. In parallel, investing in flexible manufacturing strategies and supplier diversification will mitigate exposure to trade-policy and component-sourcing disruptions while preserving capacity to scale.

Operationally, expanding clinician training infrastructures and establishing regional centers of excellence can accelerate safe adoption while ensuring consistent outcomes. These programs should be coupled with digital tools that enhance procedural planning, device sizing, and post-procedural follow-up. Commercially, negotiating outcome-based contracting and innovative reimbursement constructs can align incentives with systems that prioritize long-term patient benefit and cost containment.

Finally, executives should cultivate cross-sector partnerships that integrate device development with imaging, software, and services to provide bundled solutions that address whole-patient pathways. Prioritizing these strategic initiatives will enhance competitive positioning, reduce implementation friction, and increase the likelihood of sustained clinical and commercial success.

Transparent methodology detailing evidence synthesis, expert engagement, and validation processes used to ensure robust insights into device performance and market dynamics

The research approach combined a systematic review of peer-reviewed clinical literature, analysis of trial registries, and targeted examination of regulatory guidance documents to establish clinical context and safety considerations. This evidence base was supplemented by qualitative expert interviews with interventional cardiologists, cardiac surgeons, procurement leaders, and regulatory specialists to capture on-the-ground perspectives about adoption barriers, training needs, and device performance nuances.

Secondary sources, including technical white papers, device labeling, and procedural guideline updates, were analyzed to understand device characteristics, delivery routes, and recommended peri-procedural practices. Supply chain and manufacturing insights were derived from vendor disclosures, procurement guidelines, and public filings that illustrate sourcing models and capacity strategies. Throughout the study, evidence was triangulated to reconcile differences between clinical trial outcomes and real-world practice patterns, ensuring robust and balanced conclusions.

Quality assurance included cross-validation of interview findings against published evidence and internal peer review by multidisciplinary analysts to minimize bias. Where data gaps existed, conservative interpretation and clearly stated assumptions were used to preserve analytical integrity and to highlight areas where further study is warranted.

Concise synthesis of critical strategic takeaways to guide executive decision-making and align investments with sustainable clinical and commercial outcomes

The transcatheter heart valve domain is maturing into a complex ecosystem where device innovation, clinical practice evolution, and commercial strategy converge. Advances in device design and imaging have expanded candidate populations and optimized outcomes, while regulatory and reimbursement systems adapt to support iterative improvements and broader access. At the same time, external pressures such as trade policy and supply chain constraints are accelerating strategic responses from manufacturers and health systems alike.

Stakeholders that prioritize integrated evidence generation, flexible manufacturing, and clinician-focused training will be best positioned to convert technological advances into sustained clinical and commercial success. Moreover, coordinated engagement with payers and health systems around value-based care models will be critical to align incentives and realize broader access for eligible patients. In short, the pathway to leadership in this space requires a multidimensional strategy that combines technical excellence, operational resilience, and a clear value narrative to clinicians, payers, and hospital partners.

Collectively, these takeaways provide a framework for decision-makers to align investments, partnerships, and clinical programs so they can responsibly scale innovations that improve patient outcomes and system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Heart Valve Market, by Product Type

  • 8.1. Balloon-Expandable
  • 8.2. Mechanically Expandable
  • 8.3. Self-Expandable

9. Transcatheter Heart Valve Market, by Valve Type

  • 9.1. Aortic
  • 9.2. Mitral
  • 9.3. Pulmonary
  • 9.4. Tricuspid

10. Transcatheter Heart Valve Market, by Delivery Route

  • 10.1. Transaortic
  • 10.2. Transapical
  • 10.3. Transfemoral
  • 10.4. Transsubclavian

11. Transcatheter Heart Valve Market, by Patient Age Group

  • 11.1. Adult Patients
  • 11.2. Pediatric Patients

12. Transcatheter Heart Valve Market, by End User

  • 12.1. Ambulatory Surgical Centers & Clinics
  • 12.2. Hospitals & Cardiac Centers

13. Transcatheter Heart Valve Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transcatheter Heart Valve Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transcatheter Heart Valve Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Transcatheter Heart Valve Market

17. China Transcatheter Heart Valve Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 4C Medical Technologies, Inc.
  • 18.6. Abbott Laboratories
  • 18.7. Auto Tissue Berlin GmbH
  • 18.8. Boston Scientific Corporation
  • 18.9. Bracco S.p.A.
  • 18.10. Colibri Heart Valve, LLC
  • 18.11. CoreMedic
  • 18.12. Cryolife Inc.
  • 18.13. Edwards Lifesciences Corporation
  • 18.14. Foldax, Inc.
  • 18.15. Hansen Medical Inc. by Auris Surgical Robotics Inc.
  • 18.16. JC Medical, Inc. by Genesis Group
  • 18.17. JenaValve
  • 18.18. Lepu Medical Technology Co., Ltd
  • 18.19. LivaNova PLC
  • 18.20. Mardil Medical
  • 18.21. Medtronic PLC
  • 18.22. Meril Life Sciences
  • 18.23. NVT AG
  • 18.24. SentreHEART by AtriCure
  • 18.25. Stryker Corp.
  • 18.26. XELTIS

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER HEART VALVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCATHETER HEART VALVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY BALLOON-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY BALLOON-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY BALLOON-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MECHANICALLY EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MECHANICALLY EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MECHANICALLY EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY SELF-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY SELF-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY SELF-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSAPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSSUBCLAVIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSSUBCLAVIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY TRANSSUBCLAVIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY HOSPITALS & CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY HOSPITALS & CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY HOSPITALS & CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GCC TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. G7 TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. NATO TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL TRANSCATHETER HEART VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA TRANSCATHETER HEART VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)